Title |
Targeting Syk in Autoimmune Rheumatic Diseases
|
---|---|
Published in |
Frontiers in immunology, March 2016
|
DOI | 10.3389/fimmu.2016.00078 |
Pubmed ID | |
Authors |
Guo-Min Deng, Vasileios C. Kyttaris, George C. Tsokos |
Abstract |
Spleen tyrosine kinase (Syk) is a member of the Src family of non-receptor tyrosine kinases, which associates directly with surface receptors, including B-cell receptor and Fcγ receptor, and is involved in a variety of signal transduction pathways. Rheumatoid arthritis (RA) and systemic lupus erythematosus are autoimmune diseases in which autoantibodies, immune complexes, and autoreactive T cells account for the expression of tissue inflammation and damage. Syk inhibitors efficiently suppress RA in patients albeit in the expression of unwanted side effects, including gastrointestinal effects, hypertension, and neutropenia. Syk inhibitors also inhibit clinical manifestations in lupus-prone mice. Here, we review the evidence that supports the use of Syk inhibitors to treat rheumatic and other autoimmune diseases. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 33% |
Switzerland | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 67 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 17 | 25% |
Student > Master | 9 | 13% |
Student > Ph. D. Student | 8 | 12% |
Professor | 4 | 6% |
Student > Postgraduate | 4 | 6% |
Other | 10 | 15% |
Unknown | 15 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 15 | 22% |
Immunology and Microbiology | 13 | 19% |
Medicine and Dentistry | 8 | 12% |
Chemistry | 5 | 7% |
Agricultural and Biological Sciences | 3 | 4% |
Other | 3 | 4% |
Unknown | 20 | 30% |